Skip to content

evaluation of the effect of levothyroxine on benign thyroid nodule volume

Evaluation of the effect of levothyroxine in comparison to placebo on thyroid nodule volume in patients with benign thyroid nodule during 2 year follow up

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016092624021N2
Enrollment
80
Registered
2016-10-31
Start date
2016-09-26
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid nodule. Disorders of thyroid gland

Interventions

Intervention 1: intervention group:using levothyroxine with therapeutic dose of 1.8 µg/kg, daily, for 24 months. Intervention 2: control group:using placebo half to one tablet, daily, for 24 months.
Treatment - Drugs
Placebo
intervention group:using levothyroxine with therapeutic dose of 1.8 µg/kg, daily, for 24 months
control group:using placebo half to one tablet, daily, for 24 months

Sponsors

Guilan University of Medical Sciences, Vice chancellor for research
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:patiens with single or multi thyroid nodules that have been proved to be benign with FNA Exclusion criteria:age under 20 and over 60; hypo or hyper thyroidism; history of using levothyroxine during past year; osteoporosis ; pregnancy; cardiovascular disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Thyroid nodule volume. Timepoint: beginning of assessment,6 months later after intervention , 12 months later ,18 months later , 24 months later. Method of measurement: ultrasound.

Secondary

MeasureTime frame
TSH. Timepoint: before intervention, 6 weeks later, then every 3 months. Method of measurement: laboratory kit.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Alizadeh

Razi hospital

a_alizadeh@gums.ac.ir+98 13 3332 0370

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026